VT1093
Clinical- Indications
- Solid tumors
Company intelligence / Profile preview
Beijing WellGene Biotech
Beijing, Beijing, Chinagenevec.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Beijing WellGene Biotech has a pipeline focused on gene therapies for cancer and rare diseases. Its most advanced assets are in Phase 2 for melanoma and head & neck cancers, with another program in Phase 1/2 for epidermolysis bullosa dystrophica. The company also has preclinical candidates targeting glioma and other neoplasms[4].
- Therapeutic areas
- OncologyDermatology
- Modalities
- Gene therapyOncolytic virus therapy (for neoplasms)DNA encoding monoclonal antibody (mAb)Cytokine
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on Beijing WellGene Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Beijing WellGene Biotech.